Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of ...
Sales of Pfizer's COVID-19 products have collapsed. Thanks to heavy investment fueled by COVID-related revenue, Pfizer has a big pipeline of new potential blockbuster drugs. Cancer treatments Pfizer ...
Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first-quarter ...
Hosted on MSN
Pfizer battles another Paxlovid lawsuit from Enanta
If you don’t succeed at first, try again – in separate regions. That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement ...
The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. Paxlovid is a prescription ...
People who take Pfizer's Covid antiviral treatment Paxlovid shortly after infection may reduce their risk of developing long Covid, regardless of their age, vaccination status or infection history, ...
Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results